Related Experiment Video
Updated: Jun 20, 2026

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations
Matthew C Evans1, Josephine Barnes, Casper Nielsen
1Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK.
Objective:
To assess the relationship between MRI-derived changes in whole-brain and ventricular volume with change in cognitive scores in Alzheimer's disease (AD), mild cognitive impairment (MCI) and control subjects.
Material And Methods:
In total 131 control, 231 MCI and 99 AD subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort with T1-weighted volumetric MRIs from baseline and 12-month follow-up were used to derive volume changes. Mini mental state examination (MMSE), Alzheimer's disease assessment scale (ADAS)-cog and trails test changes were calculated over the same period.
Results:
Brain atrophy rates and ventricular enlargement differed between subject groups (p < 0.0005) and in MCI and AD were associated with MMSE changes. Both measures were additionally associated with ADAS-cog and trails-B in MCI patients, and ventricular expansion was associated with ADAS-cog in AD patients. Brain atrophy (p < 0.0005) and ventricular expansion rates (p = 0.001) were higher in MCI subjects who progressed to AD within 12 months of follow-up compared with MCI subjects who remained stable. MCI subjects who progressed to AD within 12 months had similar atrophy rates to AD subjects.
Conclusion:
Whole-brain atrophy rates and ventricular enlargement differed between patient groups and healthy controls, and tracked disease progression and psychological decline, demonstrating their relevance as biomarkers.
Insights
Brain atrophy and ventricular enlargement measured by MRI correlate with cognitive decline in Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients, serving as key biomarkers.
Area of Science:
- Neuroimaging
- Neurology
- Biomarkers
Background:
- Alzheimer's disease (AD) and mild cognitive impairment (MCI) are characterized by neurodegeneration.
- Quantifying brain changes and cognitive decline is crucial for understanding disease progression.
Purpose of the Study:
- To investigate the association between MRI-derived volumetric changes (whole-brain and ventricular) and cognitive score changes.
- To evaluate these associations across control, MCI, and AD subject groups.
Main Methods:
- Utilized T1-weighted volumetric MRIs from 131 control, 231 MCI, and 99 AD subjects (Alzheimer's Disease Neuroimaging Initiative cohort).
- Assessed changes in whole-brain and ventricular volumes over 12 months.
- Calculated changes in cognitive scores: Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog), and Trails Test.
Main Results:
- Significant differences in brain atrophy and ventricular enlargement rates were observed between subject groups (p < 0.0005).
- In MCI and AD groups, atrophy and ventricular expansion correlated with MMSE changes.
- MCI subjects progressing to AD showed higher atrophy and ventricular expansion rates compared to stable MCI subjects.
Conclusions:
- Whole-brain atrophy and ventricular enlargement rates differ significantly across control, MCI, and AD groups.
- These volumetric changes serve as relevant biomarkers for tracking disease progression and cognitive decline in AD and MCI.
More Related Videos
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Dementia l: Introduction
Dementia
The progression of dementia is generally gradual.
Cognitive Development During Adulthood